

CATABASIS PHARMACEUTICALS INC  
Form 8-K  
September 23, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **September 22, 2016**

**Catabasis Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37467**  
(Commission  
File Number)

**26-3687168**  
(IRS Employer  
Identification No.)

**One Kendall Square**  
**Bldg. 1400E, Suite B14202**  
**Cambridge, Massachusetts**  
(Address of Principal Executive Offices)

**02139**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 349-1971**

Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On September 22, 2016, Catabasis Pharmaceuticals, Inc., a Delaware corporation (the *Company*), entered into an Underwriting Agreement (the *Underwriting Agreement*) with Cowen and Company, LLC ( *Cowen* or the *Underwriter* ) relating to an underwritten offering (the *Offering* ) of 2,500,000 shares (the *Underwritten Shares* ) of the *Company*'s common stock, \$0.001 par value per share ( *Common Stock* ). The offering price of the *Underwritten Shares* is \$4.00 per share, and *Cowen* has agreed to purchase the *Underwritten Shares* from the *Company* pursuant to the *Underwriting Agreement* at a price of \$3.76 per share. Under the terms of the *Underwriting Agreement*, the *Company* has granted *Cowen* an option, exercisable for 30 days, to purchase up to an additional 375,000 shares of *Common Stock* (the *Option Shares* and together with the *Underwritten Shares*, the *Shares* ) at the offering price less the underwriting discount.

The closing of the *Offering* is expected to take place on September 28, 2016, subject to the satisfaction of customary closing conditions. The *Company* estimates that the net proceeds from the sale of the *Underwritten Shares* will be approximately \$9.2 million after deducting the underwriting discount and estimated offering expenses payable by the *Company*.

The *Shares* are being offered and sold pursuant to the *Company*'s shelf registration statement on Form S-3 (File No. 333-212382), which became effective on July 19, 2016. The *Company* has filed a prospectus supplement relating to the *Offering* with the Securities and Exchange Commission.

The *Underwriting Agreement* contains customary representations, warranties and covenants by the *Company*, customary conditions to closing, indemnification obligations of the *Company* and the *Underwriter*, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the *Underwriting Agreement* were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. Subject to certain exceptions, the *Company*, all of the *Company*'s directors and executive officers and certain of its significant stockholders also agreed not to sell or transfer any common stock of the *Company* for 90 days after September 22, 2016, without first obtaining the consent of the *Underwriter*.

The foregoing description of the material terms of the *Underwriting Agreement* is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The legal opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the *Company*, relating to the *Shares* is filed as Exhibit 5.1 to this Current Report on Form 8-K.

**Item 8.01 Other Events.**

The *Company* issued a press release on September 23, 2016 announcing the pricing of the *Offering*. The full text of the press release issued in connection with this announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K, and the information contained therein is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CATABASIS PHARMACEUTICALS, INC.

Date: September 23, 2016

By:

/s/ Jill C. Milne

Jill C. Milne  
President and Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
1.1	Underwriting Agreement, dated as of September 22, 2016, by and between the Company and Cowen and Company, LLC
5.1	Opinion of Wilmer Cutler Pickering Hale and Dorr LLP
23.1	Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
99.1	Press release issued by the Company on September 23, 2016